نتایج جستجو برای: Tenofovir disproxil fumarate

تعداد نتایج: 10210  

Journal: :The lancet. HIV 2017
Chloe Orkin Edwin DeJesus Moti Ramgopal Gordon Crofoot Peter Ruane Anthony LaMarca Anthony Mills Bernard Vandercam Joseph de Wet Jürgen Rockstroh Adriano Lazzarin Bart Rijnders Daniel Podzamczer Anders Thalme Marcel Stoeckle Danielle Porter Hui C Liu Andrew Cheng Erin Quirk Devi SenGupta Huyen Cao

BACKGROUND Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricit...

2014
Andrew Hill Saye Khoo David Back Anton Pozniak Marta Boffito

INTRODUCTION The approved dose of tenofovir disproxil fumarate, 300 mg once daily, was established in clinical trials in combination with efavirenz, which does not significantly affect tenofovir concentrations. Combining tenofovir with lopinavir/r, darunavir/r or atazanavir/r increases tenofovir concentrations, which could raise the risk of renal adverse events. Newly approved tenofovir tablets...

Journal: :The lancet. HIV 2017
Edwin DeJesus Moti Ramgopal Gordon Crofoot Peter Ruane Anthony LaMarca Anthony Mills Claudia T Martorell Joseph de Wet Hans-Jürgen Stellbrink Jean-Michel Molina Frank A Post Ignacio Pérez Valero Danielle Porter YaPei Liu Andrew Cheng Erin Quirk Devi SenGupta Huyen Cao

BACKGROUND Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability of switching to this regimen compared with ...

Journal: :Lancet 2015
Paul E Sax David Wohl Michael T Yin Frank Post Edwin DeJesus Michael Saag Anton Pozniak Melanie Thompson Daniel Podzamczer Jean Michel Molina Shinichi Oka Ellen Koenig Benoit Trottier Jaime Andrade-Villanueva Gordon Crofoot Joseph M Custodio Andrew Plummer Lijie Zhong Huyen Cao Hal Martin Christian Callebaut Andrew K Cheng Marshall W Fordyce Scott McCallister

BACKGROUND Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. METHODS In ...

AgNPs-Tragacanth conjugate gel as an eco friendly and low cost membrane was applied for the effective electromembrane extraction (EME) of Tenofovir disproxil fumarate, an important acidic and high polar (log p=1.25) antiviral drug, followed by HPLC-UV determination. The effect of various parameters on the extraction efficiency including the presence of AgNPs, tragacanth gum concentration, gel t...

Journal: :Reactions Weekly 2021

Journal: :Kidney international 2016
Christina M Wyatt

The widely used antiretroviral agent tenofovir disoproxil fumarate has been associated with proximal tubular injury and decreased glomerular filtration rate in HIV-infected individuals. Phase 3 trials of a new prodrug, tenofovir alafenamide, suggest a lower potential for kidney injury.

2013
Lillian Lou

Exploration of naturally occurring chemical structures for medicinal uses has received significant interest in drug discovery and development research in the past few decades. None have had more success or products of greater clinical efficacy than synthetic analogs of nucleosides and nucleotides, especially as antiviral drugs. Nucleos(t)ide antivirals are synthetic analogs of the natural build...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید